Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Change in Acquisitions & Divestments (2016 - 2025)

Historic Change in Acquisitions & Divestments for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q3 2025 value amounting to $272.1 million.

  • Agios Pharmaceuticals' Change in Acquisitions & Divestments rose 7266.96% to $272.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $931.1 million, marking a year-over-year increase of 897.49%. This contributed to the annual value of $818.4 million for FY2024, which is 2129.96% up from last year.
  • Agios Pharmaceuticals' Change in Acquisitions & Divestments amounted to $272.1 million in Q3 2025, which was up 7266.96% from $220.6 million recorded in Q2 2025.
  • In the past 5 years, Agios Pharmaceuticals' Change in Acquisitions & Divestments registered a high of $368.7 million during Q1 2024, and its lowest value of $134.0 million during Q1 2021.
  • For the 5-year period, Agios Pharmaceuticals' Change in Acquisitions & Divestments averaged around $223.7 million, with its median value being $198.9 million (2022).
  • As far as peak fluctuations go, Agios Pharmaceuticals' Change in Acquisitions & Divestments soared by 14784.13% in 2022, and later crashed by 5505.93% in 2023.
  • Agios Pharmaceuticals' Change in Acquisitions & Divestments (Quarter) stood at $336.9 million in 2021, then plummeted by 40.97% to $198.9 million in 2022, then dropped by 6.38% to $186.2 million in 2023, then fell by 19.36% to $150.1 million in 2024, then soared by 81.23% to $272.1 million in 2025.
  • Its last three reported values are $272.1 million in Q3 2025, $220.6 million for Q2 2025, and $288.3 million during Q1 2025.